DK2720698T3 - Fremgangsmåde til administration af 4-((1r,3s)-6-chlor-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazin og saltene deraf i behandlingen af skizofreni - Google Patents
Fremgangsmåde til administration af 4-((1r,3s)-6-chlor-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazin og saltene deraf i behandlingen af skizofreni Download PDFInfo
- Publication number
- DK2720698T3 DK2720698T3 DK12729555.8T DK12729555T DK2720698T3 DK 2720698 T3 DK2720698 T3 DK 2720698T3 DK 12729555 T DK12729555 T DK 12729555T DK 2720698 T3 DK2720698 T3 DK 2720698T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- dose
- weekly
- disorder
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (9)
1. Forbindelse (I)
til anvendelse i behandlingen afen sygdom i det centrale nervesystem, kendetegnet ved, at forbindelse (I) administreres halvugentligt eller ugentligt i en formulering med øjeblikkelig frigivelse (IR-formulering), en formulering med forlænget, kontrolleret eller forsinket frigivelse, til oral administration i en dosis svarende til mellem 20 mg/uge og 50 mg/uge, beregnet som den frie base af forbindelse (I)
2. Forbindelse (I)
ifølge krav 1 til anvendelse ifølge krav 1, hvor forbindelse (I) administreres ugentligt i en dosis, beregnet som den frie base af forbindelse (I), mellem 20 mg/dosis og 50 mg/dosis.
3. Forbindelse (I)
ifølge krav 1 eller 2 til anvendelse ifølge krav 1, hvor forbindelse (I) administreres
ugentligt i en dosis, beregnet som den frie base af forbindelse (I), mellem omkring 30 mg/dosis og omkring 45 mg/dosis.
4. Forbindelse (I)
ifølge krav 1, 2 eller 3 til anvendelse ifølge krav 1, hvor forbindelse (I) administreres ugentligt i en dosis, beregnet som den frie base af forbindelse (I), på omkring 30 mg/dosis. Forbindelse (I)
5. Forbindelse (I)
ifølge krav 1, 2 eller 3 til anvendelse ifølge krav 1, hvor forbindelse (I) administreres ugentligt i en dosis, beregnet som den frie base af forbindelse (I), på omkring 45 mg/dosis.
6. Forbindelse (I)
til anvendelse i behandlingen ifølge krav 1, hvor sygdommen er valgt fra gruppen af sygdomme bestående af psykose, i særdeleshed skizofreni eller andre sygdomme der involverer psykotiske symptomer, såsom eksempelvis skizofreni, Skizofreniform lidelse, skizoaffektiv lidelse, paranoid psykose, kortvarig psykotisk
lidelse, delt psykotisk lidelse, samt andre psykotiske lidelser eller sygdomme der forekommer med psykotiske symptomer, eksempelvis bipolar lidelse, såsom mani i bipolar lidelse, og til behandling af psykose i Parkinsons sygdom.
7. Forbindelse (I)
ifølge krav 1 til anvendelse ifølge krav 1 og en yderligere forbindelse valgt fra gruppen bestående af sertindol, olanzapin, risperidon, quetiapin, aripiprazol, haloperidol, clozapin, ziprasidon og osanetant til anvendelse i behandlingen af psykose, i særdeleshed skizofreni eller andre sygdomme der involverer psykotiske symptomer, såsom eksempelvis skizofreniform lidelse, skizoaffektiv lidelse, paranoid psykose, kortvarig psykotisk lidelse, delt psykotisk lidelse, samt andre psykotiske lidelser eller sygdomme der forekommer med psykotiske symptomer, eksempelvis bipolar lidelse, såsom mani i bipolar lidelse, og til behandling af psykose i Parkinsons sygdom, hvor forbindelse (I) administreres halvugentligt eller ugentligt i en formulering med øjeblikkelig frigivelse (IR-formulering), en formulering med forlænget, kontrolleret eller forsinket frigivelse, til oral administration i en dosis svarende til mellem 20 mg/uge og 50 mg/uge beregnet som den frie base af forbindelse (I).
8. Farmaceutisk sammensætning omfattende Forbindelse (I)
eller et salt af forbindelse (I) og en eller flere farmaceutisk acceptable bærere,
fortyndingsmidler og excipienser til anvendelse i behandlingen afen sygdom i det centrale nervesystem, i særdeleshed psykose, såsom skizofreni, kendetegnet ved, at den farmaceutiske sammensætning omfattende forbindelse (I) administreres halvugentligt eller ugentligt i en formulering med øjeblikkelig frigivelse (IR-formulering), en formulering med forlænget, kontrolleret eller forsinket frigivelse til oral administration.
9. Den farmaceutiske sammensætning ifølge krav 8 til anvendelse ifølge krav 8 yderligere omfattende et eller flere neuroleptiske midler valgt fra sertindol, olanzapin, risperidon, quetiapin, aripiprazol, haloperidol, clozapin, ziprasidon og osanetant.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161498653P | 2011-06-20 | 2011-06-20 | |
DKPA201100465 | 2011-06-20 | ||
PCT/EP2012/061779 WO2012175531A1 (en) | 2011-06-20 | 2012-06-20 | Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2720698T3 true DK2720698T3 (da) | 2018-11-26 |
Family
ID=58794324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12729555.8T DK2720698T3 (da) | 2011-06-20 | 2012-06-20 | Fremgangsmåde til administration af 4-((1r,3s)-6-chlor-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazin og saltene deraf i behandlingen af skizofreni |
Country Status (22)
Country | Link |
---|---|
US (1) | US9610287B2 (da) |
EP (1) | EP2720698B1 (da) |
JP (1) | JP6140151B2 (da) |
KR (1) | KR101900989B1 (da) |
CN (1) | CN103608015A (da) |
AU (1) | AU2012274150B2 (da) |
BR (1) | BR112013032178A2 (da) |
CA (1) | CA2838055C (da) |
DK (1) | DK2720698T3 (da) |
ES (1) | ES2694298T3 (da) |
HR (1) | HRP20181684T1 (da) |
IL (1) | IL230060A (da) |
JO (1) | JO3421B1 (da) |
LT (1) | LT2720698T (da) |
MX (1) | MX349754B (da) |
PL (1) | PL2720698T3 (da) |
RS (1) | RS57944B1 (da) |
RU (1) | RU2613177C2 (da) |
SI (1) | SI2720698T1 (da) |
TW (1) | TWI552751B (da) |
WO (1) | WO2012175531A1 (da) |
ZA (1) | ZA201309617B (da) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7402400B2 (en) | 2001-07-03 | 2008-07-22 | Regents Of The University Of California | Mammalian sweet taste receptors |
EP1229781B1 (en) | 1999-11-17 | 2013-01-02 | Mendel Biotechnology, Inc. | Seed trait genes |
US6458538B1 (en) | 1999-12-14 | 2002-10-01 | Ptc Therapeutics, Inc. | Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay |
TW201006846A (en) | 2000-03-07 | 2010-02-16 | Senomyx Inc | T1R taste receptor and genes encidung same |
EP2410060A1 (en) | 2000-08-22 | 2012-01-25 | Mendel Biotechnology, Inc. | Genes for modifying plant traits IV |
US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
US7883856B2 (en) | 2001-04-05 | 2011-02-08 | Senomyx Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
EP2003451B1 (en) | 2001-06-26 | 2012-05-30 | Senomyx, Inc. | T1r1-t1r3 hetero-oligomeric umami taste receptors and cell lines that express said receptors and use thereof for identification of umami taste compounds |
US7871619B2 (en) | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
EP2436774A3 (en) | 2002-08-01 | 2012-06-13 | The Regents of The University of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
AU2003243151A1 (en) | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
ES2380017T3 (es) | 2002-09-18 | 2012-05-07 | Mendel Biotechnology, Inc. | Polinucleótidos y polipéptidos en plantas |
SI1629088T1 (sl) | 2003-05-30 | 2012-08-31 | Agensys Inc | Antigen izvornih celic prostate (psca) in njegova podzaporedja |
EP2369348A1 (en) | 2003-11-07 | 2011-09-28 | Ciphergen Biosystems, Inc. | Biomarkers for Alzheimer's disease |
WO2005060739A1 (en) | 2003-12-24 | 2005-07-07 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
DK1734996T3 (da) | 2004-04-02 | 2013-06-10 | Univ California | Fremgangsmåder og sammensætninger til behandling og forebyggelse af sygdom, der er associeret med alfa v beta 5-integrin |
US7939251B2 (en) | 2004-05-06 | 2011-05-10 | Roche Molecular Systems, Inc. | SENP1 as a marker for cancer |
AU2005250370B2 (en) | 2004-05-28 | 2010-04-01 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
DK2453024T3 (da) | 2004-06-21 | 2018-02-12 | Univ Leland Stanford Junior | Gener og ledningsveje, der eksprimeres forskelligt i bipolar lidelse og/eller større depressiv lidelse |
US7850960B2 (en) | 2004-12-30 | 2010-12-14 | University Of Washington | Methods for regulation of stem cells |
EP2153848A3 (en) | 2005-01-27 | 2010-07-21 | The Regents of the University of California | Therapeutic monoclonal antibodies that neutralize botulinium neurotoxins |
JP4324636B2 (ja) | 2005-03-31 | 2009-09-02 | アジェンシス,インコーポレイテッド | 161p2f10bタンパク質に結合する抗体および関連分子 |
HUE040063T2 (hu) | 2005-07-19 | 2019-02-28 | Stemgen S P A | Tumor õssejtek tumorképzõ potenciáljának gátlása BMP-4 segítségével |
EP1937718B1 (en) | 2005-10-20 | 2017-12-06 | Senomyx, Inc. | Chimeric human sweet-umami and umami-sweet taste receptors |
NZ568762A (en) | 2005-11-07 | 2011-11-25 | Scripps Research Inst | Use of an inhibitor of tissue factor signaling in the manufacture of a medcament for inhibiting or suppressing tissue factor/tissue factor VIIa signaling involving protease activated receptor 2 in a mammal |
CA2629299C (en) | 2005-11-12 | 2017-08-22 | The Board Of Trustees Of The Leland Stanford Junior University | Fgf2-related methods for diagnosing and treating depression |
CN103301475B (zh) | 2005-12-28 | 2016-08-03 | 斯克里普斯研究所 | 药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用 |
US20100278821A1 (en) | 2006-03-21 | 2010-11-04 | The Regents Of The University Of California | N-cadherin: target for cancer diagnosis and therapy |
CA2646597A1 (en) | 2006-03-21 | 2007-09-27 | The Regents Of The University Of California | N-cadherin and ly6 e: targets for cancer diagnosis and therapy |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
US20100292090A1 (en) | 2006-08-25 | 2010-11-18 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
NZ575090A (en) | 2006-09-06 | 2012-02-24 | Univ California | Molecular diagnosis and classification of malignant melanoma using RGS1, ARPC2, FN1, SPP1 and WNT-2 polypeptide markers |
EP2095100B1 (en) | 2006-11-22 | 2016-09-21 | President and Fellows of Harvard College | Method of operating a nanowire field effect transistor sensor |
EP2581081A3 (en) | 2007-06-01 | 2013-07-31 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
EP2522755B1 (en) | 2007-08-13 | 2014-04-02 | Baxter International Inc. | IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease |
US7939671B2 (en) | 2007-08-21 | 2011-05-10 | Senomyx, Inc. | Compounds that inhibit (block) bitter taste in composition and use thereof |
JP5496897B2 (ja) | 2007-10-04 | 2014-05-21 | ザイモジェネティクス, インコーポレイテッド | B7ファミリーメンバーのzB7H6ならびに関連する組成物および方法 |
EP2212693B1 (en) | 2007-10-22 | 2015-04-22 | The Regents of The University of California | Biomarkers for prenatal diagnosis of congenital cytomegalovirus |
WO2009062112A2 (en) | 2007-11-09 | 2009-05-14 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as antimicrobials |
SG10201607710UA (en) | 2008-03-17 | 2016-11-29 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
ES2613844T3 (es) | 2008-04-21 | 2017-05-26 | Lawrence Livermore National Security, Llc | Ligandos polidentados de alta afinidad selectivos y métodos para producirlos |
EP2324044A4 (en) | 2008-08-04 | 2012-04-25 | Univ Miami | STING (INTERFERON GENE STIMULATOR), A REGULATOR OF INDIAN IMMUNE RESPONSES |
AU2009298879A1 (en) | 2008-09-23 | 2010-04-08 | President And Fellows Of Harvard College | SIRT4 and uses thereof |
EP3260123A1 (en) | 2008-11-06 | 2017-12-27 | University of Miami | Role of soluble upar in the pathogenesis of proteinuric kidney disease |
EP2687609B1 (en) | 2008-11-10 | 2017-01-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Method for treating solid tumor |
EP2789618B1 (en) | 2008-12-03 | 2016-07-27 | The Scripps Research Institute | Stem cell cultures |
CA2747398C (en) | 2008-12-17 | 2023-06-20 | The Scripps Research Institute | Generation and maintenance of stem cells |
KR20110140128A (ko) | 2009-03-27 | 2011-12-30 | 고조 인더스트리즈, 인크 | 포자-표면 상호작용을 길항하는 화합물을 스크리닝 및 사용하기 위한 조성물 및 방법 |
KR101752515B1 (ko) | 2009-07-24 | 2017-06-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Avb5 인테그린과 결부된 질환의 치료 및 예방을 위한 방법 및 조성물 |
JP5823964B2 (ja) | 2009-08-14 | 2015-11-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 自閉症を診断及び治療する方法 |
WO2011022638A1 (en) | 2009-08-20 | 2011-02-24 | Transposagen Biopharmaceuticals, Inc. | Trp inhibitors and uses thereof |
WO2011038228A1 (en) | 2009-09-24 | 2011-03-31 | President And Fellows Of Harvard College | Bent nanowires and related probing of species |
ES2365343B1 (es) | 2009-11-19 | 2012-07-10 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de cd98 como marcador de receptividad endometrial. |
WO2011094759A2 (en) | 2010-02-01 | 2011-08-04 | The Regents Of The University Of California | Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies |
WO2012052391A1 (en) | 2010-10-19 | 2012-04-26 | Glaxo Group Limited | Polypeptide with jmjd3 catalytic activity |
WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
WO2012119989A2 (en) | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
US20120301904A1 (en) | 2011-04-26 | 2012-11-29 | Prosetta Antiviral, Inc | Multiprotein assemblies |
EP2825209B1 (en) | 2012-03-14 | 2018-08-29 | University of Central Florida Research Foundation, Inc. | Neurofibromatoses therapeutic agents and screening for same |
JP6399660B2 (ja) | 2012-04-10 | 2018-10-03 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | 癌治療用組成物および方法 |
KR20150023287A (ko) | 2012-04-24 | 2015-03-05 | 더 유니버시티 오브 마이애미 | 침습성 및 다중약물 내성 병원체에 대한 퍼포린 2 방어 |
CA2879542A1 (en) | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
US9750705B2 (en) | 2012-08-31 | 2017-09-05 | The Regents Of The University Of California | Agents useful for treating obesity, diabetes and related disorders |
AU2013204200B2 (en) | 2012-10-11 | 2016-10-20 | Brandeis University | Treatment of amyotrophic lateral sclerosis |
US20140120116A1 (en) | 2012-10-26 | 2014-05-01 | The Chinese University Of Hong Kong | Treatment of cancer using smad3 inhibitor |
WO2014124339A2 (en) | 2013-02-07 | 2014-08-14 | The Regents Of The University Of California | Use of translational profiling to identify target molecules for therapeutic treatment |
US9428537B2 (en) | 2013-03-15 | 2016-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | tRNA derived small RNAs (tsRNAs) involved in cell viability |
CA2933590C (en) | 2013-12-11 | 2023-10-03 | Sloan-Kettering Institute For Cancer Research | Glucocorticoid inhibitors for treatment of prostate cancer |
EP3444251B1 (en) | 2013-12-11 | 2023-06-07 | Biogen MA Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
WO2015136509A2 (en) | 2014-03-14 | 2015-09-17 | Genesis Theranostix Korlatolt Felelossegu Tarsasag | Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy |
WO2016195982A2 (en) | 2015-06-01 | 2016-12-08 | The Penn State Research Foundation | Hepatitis b virus capsid assembly |
US10782304B2 (en) | 2015-06-24 | 2020-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for detecting protein-protein interactions |
WO2018036503A1 (en) | 2016-08-25 | 2018-03-01 | The Chinese University Of Hong Kong | Fecal bacterial markers for colorectal cancer |
RU2019121922A (ru) | 2016-12-15 | 2021-01-18 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Композиции и способы лечения рака |
WO2018175324A1 (en) | 2017-03-20 | 2018-09-27 | The Broad Institute, Inc. | Compounds and methods for regulating insulin secretion |
EP3873488A4 (en) | 2018-10-31 | 2022-08-03 | The University of Sydney | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRUS INFECTION |
US11325978B2 (en) | 2018-11-06 | 2022-05-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for treating beta-globinopathies |
WO2023081167A2 (en) | 2021-11-02 | 2023-05-11 | The Regents Of The University Of California | P-selectin mutants and modulation of integrin-mediated signaling |
WO2023146807A1 (en) | 2022-01-25 | 2023-08-03 | The Regents Of The University Of California | Vegf mutants and modulation of integrin-mediated signaling |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK55192D0 (da) | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindenderivater |
JP5043429B2 (ja) | 2003-08-18 | 2012-10-10 | ハー・ルンドベック・アクチエゼルスカベット | トランス−4−((1r,3s)−6−クロロ−3−フェニルインダン−1−イル)−1,2,2−トリメチルピペラジンのコハク酸塩およびマロン酸塩、および薬剤としての使用方法 |
WO2005102342A1 (en) * | 2004-04-22 | 2005-11-03 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders ii |
EP1909689A4 (en) | 2005-07-18 | 2011-11-16 | Univ Pennsylvania | IMPLANTS CONTAINING A MEDICAMENT AND METHOD OF USE |
BRPI0912223A2 (pt) * | 2008-05-07 | 2015-10-06 | Lundbeck & Co As H | métodos para melhorar funcionamento cognitivo e para tratar uma doença, composto, uso do mesmo, e, composição farmacêutica. |
EA201170512A1 (ru) * | 2008-10-03 | 2011-08-30 | Х. Лундбекк А/С | Композиция для перорального введения |
AU2010264670A1 (en) * | 2009-06-24 | 2012-01-19 | Merck Sharp & Dohme B.V. | Injectable formulations containing asenapine and method of treatment using same |
-
2012
- 2012-06-19 TW TW101121870A patent/TWI552751B/zh not_active IP Right Cessation
- 2012-06-19 JO JOP/2012/0162A patent/JO3421B1/ar active
- 2012-06-20 SI SI201231436T patent/SI2720698T1/sl unknown
- 2012-06-20 KR KR1020137033338A patent/KR101900989B1/ko not_active Application Discontinuation
- 2012-06-20 LT LTEP12729555.8T patent/LT2720698T/lt unknown
- 2012-06-20 PL PL12729555T patent/PL2720698T3/pl unknown
- 2012-06-20 RU RU2014101482A patent/RU2613177C2/ru active
- 2012-06-20 ES ES12729555.8T patent/ES2694298T3/es active Active
- 2012-06-20 CN CN201280029452.1A patent/CN103608015A/zh active Pending
- 2012-06-20 WO PCT/EP2012/061779 patent/WO2012175531A1/en active Application Filing
- 2012-06-20 JP JP2014516318A patent/JP6140151B2/ja active Active
- 2012-06-20 DK DK12729555.8T patent/DK2720698T3/da active
- 2012-06-20 RS RS20181311A patent/RS57944B1/sr unknown
- 2012-06-20 MX MX2013014978A patent/MX349754B/es active IP Right Grant
- 2012-06-20 BR BR112013032178A patent/BR112013032178A2/pt not_active Application Discontinuation
- 2012-06-20 US US14/126,499 patent/US9610287B2/en active Active
- 2012-06-20 AU AU2012274150A patent/AU2012274150B2/en not_active Ceased
- 2012-06-20 CA CA2838055A patent/CA2838055C/en not_active Expired - Fee Related
- 2012-06-20 EP EP12729555.8A patent/EP2720698B1/en active Active
-
2013
- 2013-12-19 IL IL230060A patent/IL230060A/en active IP Right Grant
- 2013-12-19 ZA ZA2013/09617A patent/ZA201309617B/en unknown
-
2018
- 2018-10-16 HR HRP20181684TT patent/HRP20181684T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
PL2720698T3 (pl) | 2019-01-31 |
JP6140151B2 (ja) | 2017-05-31 |
JP2014517050A (ja) | 2014-07-17 |
TW201306840A (zh) | 2013-02-16 |
CA2838055C (en) | 2021-01-26 |
LT2720698T (lt) | 2018-11-12 |
KR20140033419A (ko) | 2014-03-18 |
TWI552751B (zh) | 2016-10-11 |
HRP20181684T1 (hr) | 2018-12-14 |
ZA201309617B (en) | 2015-04-29 |
WO2012175531A1 (en) | 2012-12-27 |
MX349754B (es) | 2017-08-11 |
AU2012274150B2 (en) | 2016-10-06 |
SI2720698T1 (sl) | 2018-12-31 |
IL230060A (en) | 2017-10-31 |
CA2838055A1 (en) | 2012-12-27 |
EP2720698B1 (en) | 2018-10-03 |
RU2014101482A (ru) | 2015-07-27 |
BR112013032178A2 (pt) | 2016-12-20 |
EP2720698A1 (en) | 2014-04-23 |
RS57944B1 (sr) | 2019-01-31 |
US9610287B2 (en) | 2017-04-04 |
KR101900989B1 (ko) | 2018-09-20 |
AU2012274150A1 (en) | 2014-01-09 |
CN103608015A (zh) | 2014-02-26 |
MX2013014978A (es) | 2014-04-10 |
ES2694298T3 (es) | 2018-12-19 |
JO3421B1 (ar) | 2019-10-20 |
RU2613177C2 (ru) | 2017-03-15 |
US20140194409A1 (en) | 2014-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2720698T3 (da) | Fremgangsmåde til administration af 4-((1r,3s)-6-chlor-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazin og saltene deraf i behandlingen af skizofreni | |
Meyer et al. | Lurasidone: a new drug in development for schizophrenia | |
Potkin et al. | Efficacy and tolerability of asenapine in acute schizophrenia: a placebo-and risperidone-controlled trial. | |
Miyamoto et al. | Antipsychotic drugs | |
Jibson | Second-generation antipsychotic medications: Pharmacology, administration, and side effects | |
Schmidt et al. | A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D2 receptor antagonist in the treatment of acute exacerbation of schizophrenia | |
CN1694701A (zh) | 治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂 | |
US6960577B2 (en) | Combination therapy for treatment of refractory depression | |
R Moore et al. | Pharmacogenomics in psychiatry: implications for practice | |
AU4008699A (en) | Combination therapy for treatment of refractory depression | |
Albers et al. | Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? | |
McIntyre | Asenapine: a review of acute and extension phase data in bipolar disorder | |
Vajda et al. | Current approaches to management of depression in Parkinson’s disease | |
Meltzer et al. | Asenapine. | |
Aukst-Margetić et al. | An open-label series using loratadine for the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors | |
Neves et al. | Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiperazine antipsychotic prototypes LASSBio-579 and LASSBio-581 | |
TR201816155T4 (tr) | Şizofreni tedavisinde 4-((1r,3s)-6-kloro-3-fenil-indan-1-il)-1,2,2-trimetil-piperazin ve bunların tuzlarının uygulanmasına yönelik yöntem. | |
Cetin | Asenapine: A novel hope in the treatment of schizophrenia and manic and mixed episodes of bipolar I disorder | |
Orsolini et al. | Atypical antipsychotics in major depressive disorder | |
Madhusoodanan et al. | of Schizophrenia and Psychoses in Older Adults: Psychopharmacological Approaches | |
McCutcheon et al. | Drugs to treat schizophrenia and psychosis (Dopamine antagonists and partial agonists other than clozapine) | |
Mauri | Antidepressant Efficacy of the Antipsychotic Quetiapine: Pharmacokinetics, Pharmacodynamics and Clinical Data | |
Guiroy et al. | Role of Antipsychotics in Mood Disorder Treatment | |
Canu | Action of atypical antipsychotics on body weight and associated metabolic factors | |
Remington | ‘Atypical’antipsychotics: where does ziprasidone fit? |